Liu, K.W.; Pajtler, K.W.; Worst, B.C.; Pfister, S.M.; Wechsler-Reya, R.J. Molecular mechanisms and therapeutic targets in pediatric brain tumors. Sci. Signal., 2017, 10(470), eaaf7593.
[http://dx.doi.org/10.1126/scisignal.aaf7593] [PMID: 28292958]

Ostrom, Q.T.; Gittleman, H.; Farah, P.; Ondracek, A.; Chen, Y.; Wolinsky, Y.; Stroup, N.E.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neurooncol., 2013, 15(Suppl. 2), ii1-ii56.
[http://dx.doi.org/10.1093/neuonc/not151] [PMID: 24137015]

Macdonald, T.J.; Aguilera, D.; Castellino, R.C. The rationale] for targeted therapies in medulloblastoma. Neuro. Oncol., 2014, 16(11), 9-20.
[http://dx.doi.org/10.1093/neuonc/not147]

Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; Soffietti, R.; von Deimling, A.; Ellison, D.W. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-oncol., 2021, 23(8), 1231-1251.
[http://dx.doi.org/10.1093/neuonc/noab106] [PMID: 34185076]

Abedalthagafi, M.; Mobark, N.; Al-Rashed, M.; AlHarbi, M. Epigenomics and immunotherapeutic advances in pediatric brain tumors. NPJ Precis. Oncol., 2021, 5(1), 34.
[http://dx.doi.org/10.1038/s41698-021-00173-4] [PMID: 33931704]

Lu, Y.; Chan, Y. T.; Tan, H. Y.; Li, S.; Wang, N.; Feng, Y. Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy. Mol. Cancer, 2020, 19(1), 1-16.
[http://dx.doi.org/10.1186/s12943-020-01197-3]

Cosgrove, M.S.; Boeke, J.D.; Wolberger, C. Regulated nucleosome mobility and the histone code. Nat. Struct. Mol. Biol., 2004, 11(11), 1037-1043.
[http://dx.doi.org/10.1038/nsmb851] [PMID: 15523479]

Khorasanizadeh, S. The nucleosome. Cell, 2004, 116(2), 259-272.
[http://dx.doi.org/10.1016/S0092-8674(04)00044-3] [PMID: 14744436]

Greer, E.L.; Shi, Y. Histone methylation: A dynamic mark in health, disease and inheritance. Nat. Rev. Genet., 2012, 13(5), 343-357.
[http://dx.doi.org/10.1038/nrg3173] [PMID: 22473383]

Priesterbach-Ackley, L.P.; Boldt, H.B.; Petersen, J.K.; Bervoets, N.; Scheie, D.; Ulhøi, B.P.; Gardberg, M.; Brännström, T.; Torp, S.H.; Aronica, E.; Küsters, B.; den Dunnen, W.F.A.; Vos, F.Y.F.L.; Wesseling, P.; Leng, W.W.J.; Kristensen, B.W. Brain tumour diagnostics using a DNA methylation‐based classifier as a diagnostic support tool. Neuropathol. Appl. Neurobiol., 2020, 46(5), 478-492.
[http://dx.doi.org/10.1111/nan.12610] [PMID: 32072658]

Nebbioso, A.; Tambaro, F.P.; Dell’Aversana, C.; Altucci, L. Cancer epigenetics: Moving forward. PLoS Genet., 2018, 14(6), e1007362.
[http://dx.doi.org/10.1371/journal.pgen.1007362] [PMID: 29879107]

Souweidane, M.M.; Kramer, K.; Pandit-Taskar, N.; Zhou, Z.; Haque, S.; Zanzonico, P.; Carrasquillo, J.A.; Lyashchenko, S.K.; Thakur, S.B.; Donzelli, M.; Turner, R.S.; Lewis, J.S.; Cheung, N.K.V.; Larson, S.M.; Dunkel, I.J. Convection-enhanced delivery for diffuse intrinsic pontine glioma: A single-centre, dose-escalation, phase 1 trial. Lancet Oncol., 2018, 19(8), 1040-1050.
[http://dx.doi.org/10.1016/S1470-2045(18)30322-X] [PMID: 29914796]

Schwalbe, E.C.; Lindsey, J.C.; Nakjang, S.; Crosier, S.; Smith, A.J.; Hicks, D.; Rafiee, G.; Hill, R.M.; Iliasova, A.; Stone, T.; Pizer, B.; Michalski, A.; Joshi, A.; Wharton, S.B.; Jacques, T.S.; Bailey, S.; Williamson, D.; Clifford, S.C. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study. Lancet Oncol., 2017, 18(7), 958-971.
[http://dx.doi.org/10.1016/S1470-2045(17)30243-7] [PMID: 28545823]

Hovestadt, V.; Ayrault, O.; Swartling, F.J.; Robinson, G.W.; Pfister, S.M.; Northcott, P.A. Medulloblastomics revisited: Biological and clinical insights from thousands of patients. Nat. Rev. Cancer, 2020, 20(1), 42-56.
[http://dx.doi.org/10.1038/s41568-019-0223-8] [PMID: 31819232]

Kumar, R.; Liu, A.P.Y.; Northcott, P.A. Medulloblastoma genomics in the modern molecular era. Brain Pathol., 2020, 30(3), 679-690.
[http://dx.doi.org/10.1111/bpa.12804] [PMID: 31799776]

Cavalli, F.M.G.; Remke, M.; Rampasek, L.; Peacock, J.; Shih, D.J.H.; Luu, B.; Garzia, L.; Torchia, J.; Nor, C.; Morrissy, A.S.; Agnihotri, S.; Thompson, Y.Y.; Kuzan-Fischer, C.M.; Farooq, H.; Isaev, K.; Daniels, C.; Cho, B.K.; Kim, S.K.; Wang, K.C.; Lee, J.Y.; Grajkowska, W.A.; Perek-Polnik, M.; Vasiljevic, A.; Faure-Conter, C.; Jouvet, A.; Giannini, C.; Nageswara Rao, A.A.; Li, K.K.W.; Ng, H.K.; Eberhart, C.G.; Pollack, I.F.; Hamilton, R.L.; Gillespie, G.Y.; Olson, J.M.; Leary, S.; Weiss, W.A.; Lach, B.; Chambless, L.B.; Thompson, R.C.; Cooper, M.K.; Vibhakar, R.; Hauser, P.; van Veelen, M.L.C.; Kros, J.M.; French, P.J.; Ra, Y.S.; Kumabe, T.; López-Aguilar, E.; Zitterbart, K.; Sterba, J.; Finocchiaro, G.; Massimino, M.; Van Meir, E.G.; Osuka, S.; Shofuda, T.; Klekner, A.; Zollo, M.; Leonard, J.R.; Rubin, J.B.; Jabado, N.; Albrecht, S.; Mora, J.; Van Meter, T.E.; Jung, S.; Moore, A.S.; Hallahan, A.R.; Chan, J.A.; Tirapelli, D.P.C.; Carlotti, C.G.; Fouladi, M.; Pimentel, J.; Faria, C.C.; Saad, A.G.; Massimi, L.; Liau, L.M.; Wheeler, H.; Nakamura, H.; Elbabaa, S.K.; Perezpeña-Diazconti, M.; Chico Ponce de León, F.; Robinson, S.; Zapotocky, M.; Lassaletta, A.; Huang, A.; Hawkins, C.E.; Tabori, U.; Bouffet, E.; Bartels, U.; Dirks, P.B.; Rutka, J.T.; Bader, G.D.; Reimand, J.; Goldenberg, A.; Ramaswamy, V.; Taylor, M.D. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 2017, 31(6), 737-754.e6.
[http://dx.doi.org/10.1016/j.ccell.2017.05.005] [PMID: 28609654]

Packer, R.J.; Gajjar, A.; Vezina, G.; Rorke-Adams, L.; Burger, P.C.; Robertson, P.L.; Bayer, L.; LaFond, D.; Donahue, B.R.; Marymont, M.H.; Muraszko, K.; Langston, J.; Sposto, R. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol., 2006, 24(25), 4202-4208.
[http://dx.doi.org/10.1200/JCO.2006.06.4980] [PMID: 16943538]

Needle, M.N.; Goldwein, J.W.; Grass, J.; Cnaan, A.; Bergman, I.; Molloy, P.; Sutton, L.; Zhao, H.; Garvin, J.H., Jr; Phillips, P.C. Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood. Cancer, 1997, 80(2), 341-347.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19970715)80:2<341::AID-CNCR23>3.0.CO;2-T] [PMID: 9217048]

Gajjar, A.; Finlay, J.L. The management of children and adolescents with medulloblastoma in low and middle income countries. Pediatr. Blood Cancer, 2015, 62(4), 549-550.
[http://dx.doi.org/10.1002/pbc.25371] [PMID: 25545387]

Roussel, M.F.; Stripay, J.L. Epigenetic drivers in pediatric medulloblastoma. Cerebellum, 2018, 17(1), 28-36.
[http://dx.doi.org/10.1007/s12311-017-0899-9] [PMID: 29178021]

Azzolin, L.; Panciera, T.; Soligo, S.; Enzo, E.; Bicciato, S.; Dupont, S.; Bresolin, S.; Frasson, C.; Basso, G.; Guzzardo, V.; Fassina, A.; Cordenonsi, M.; Piccolo, S. YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell, 2014, 158(1), 157-170.
[http://dx.doi.org/10.1016/j.cell.2014.06.013] [PMID: 24976009]

Shi, X.; Zhang, Z.; Zhan, X.; Cao, M.; Satoh, T.; Akira, S.; Shpargel, K.; Magnuson, T.; Li, Q.; Wang, R.; Wang, C.; Ge, K.; Wu, J. An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth. Nat. Commun., 2014, 5(1), 5425.
[http://dx.doi.org/10.1038/ncomms6425] [PMID: 25370275]

Ivanov, D.P.; Coyle, B.; Walker, D.A.; Grabowska, A.M. In vitro models of medulloblastoma: Choosing the right tool for the job. J. Biotechnol., 2016, 236, 10-25.
[http://dx.doi.org/10.1016/j.jbiotec.2016.07.028] [PMID: 27498314]

Guerreiro Stucklin, A.S.; Ramaswamy, V.; Daniels, C.; Taylor, M.D. Review of molecular classification and treatment implications of pediatric brain tumors. Curr. Opin. Pediatr., 2018, 30(1), 3-9.
[http://dx.doi.org/10.1097/MOP.0000000000000562] [PMID: 29315108]

Gajjar, A.; Chintagumpala, M.; Ashley, D.; Kellie, S.; Kun, L.E.; Merchant, T.E.; Woo, S.; Wheeler, G.; Ahern, V.; Krasin, M.J.; Fouladi, M.; Broniscer, A.; Krance, R.; Hale, G.A.; Stewart, C.F.; Dauser, R.; Sanford, R.A.; Fuller, C.; Lau, C.; Boyett, J.M.; Wallace, D.; Gilbertson, R.J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol., 2006, 7(10), 813-820.
[http://dx.doi.org/10.1016/S1470-2045(06)70867-1] [PMID: 17012043]

Clifford, S.C.; Lusher, M.E.; Lindsey, J.C.; Langdon, J.A.; Gilbertson, R.J.; Straughton, D.; Ellison, D.W. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 2006, 5(22), 2666-2670.
[http://dx.doi.org/10.4161/cc.5.22.3446] [PMID: 17172831]

Gururangan, S.; Schroeder, K.; Pediatric, G.; Services, C.; Tisch, P.R.; Tumor, B. Molecular variants and mutations in medulloblastoma. Pharm. Genomics Pers. Med., 2014, 7, 43-51.
[http://dx.doi.org/10.2147/PGPM.S38698] [PMID: 24523595]

Robinson, G.; Parker, M.; Kranenburg, T.A.; Lu, C.; Chen, X.; Ding, L.; Phoenix, T.N.; Hedlund, E.; Wei, L.; Zhu, X.; Chalhoub, N.; Baker, S.J.; Huether, R.; Kriwacki, R.; Curley, N.; Thiruvenkatam, R.; Wang, J.; Wu, G.; Rusch, M.; Hong, X.; Becksfort, J.; Gupta, P.; Ma, J.; Easton, J.; Vadodaria, B.; Onar-Thomas, A.; Lin, T.; Li, S.; Pounds, S.; Paugh, S.; Zhao, D.; Kawauchi, D.; Roussel, M.F.; Finkelstein, D.; Ellison, D.W.; Lau, C.C.; Bouffet, E.; Hassall, T.; Gururangan, S.; Cohn, R.; Fulton, R.S.; Fulton, L.L.; Dooling, D.J.; Ochoa, K.; Gajjar, A.; Mardis, E.R.; Wilson, R.K.; Downing, J.R.; Zhang, J.; Gilbertson, R.J. Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, 488(7409), 43-48.
[http://dx.doi.org/10.1038/nature11213] [PMID: 22722829]

Ellison, D.W.; Onilude, O.E.; Lindsey, J.C.; Lusher, M.E.; Weston, C.L.; Taylor, R.E.; Pearson, A.D.; Clifford, S.C. β-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J. Clin. Oncol., 2005, 23(31), 7951-7957.
[http://dx.doi.org/10.1200/JCO.2005.01.5479] [PMID: 16258095]

Dubuc, A.M.; Remke, M.; Korshunov, A.; Northcott, P.A.; Zhan, S.H.; Mendez-Lago, M.; Kool, M.; Jones, D.T.W.; Unterberger, A.; Morrissy, A.S.; Shih, D.; Peacock, J.; Ramaswamy, V.; Rolider, A.; Wang, X.; Witt, H.; Hielscher, T.; Hawkins, C.; Vibhakar, R.; Croul, S.; Rutka, J.T.; Weiss, W.A.; Jones, S.J.M.; Eberhart, C.G.; Marra, M.A.; Pfister, S.M.; Taylor, M.D. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol., 2013, 125(3), 373-384.
[http://dx.doi.org/10.1007/s00401-012-1070-9] [PMID: 23184418]

Cohen, K.J.; Pollack, I.F.; Zhou, T.; Buxton, A.; Holmes, E.J.; Burger, P.C.; Brat, D.J.; Rosenblum, M.K.; Hamilton, R.L.; Lavey, R.S.; Heideman, R.L. Temozolomide in the treatment of high-grade gliomas in children: A report from the Children’s Oncology Group. Neuro-oncol., 2011, 13(3), 317-323.
[http://dx.doi.org/10.1093/neuonc/noq191] [PMID: 21339192]

Harutyunyan, A. S.; Krug, B.; Chen, H.; Papillon-Cavanagh, S.; Zeinieh, M.; De Jay, N.; Deshmukh, S.; Chen, C. C. L.; Belle, J.; Mikael, L. G.; Marchione, D. M.; Li, R.; Nikbakht, H.; Hu, B.; Cagnone, G.; Cheung, W. A.; Mohammadnia, A.; Bechet, D.; Faury, D.; McConechy, M. K.; Pathania, M.; Jain, S. U.; Ellezam, B.; Weil, A. G.; Montpetit, A.; Salomoni, P.; Pastinen, T.; Lu, C.; Lewis, P. W.; Garcia, B. A.; Kleinman, C. L.; Jabado, N.; Majewski, J. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/Me3 and is essential for glioma tumorigenesis. Nat. Commun., 2019, 10(1), 1-13.
[http://dx.doi.org/10.1038/s41467-019-09140-x]

Khuong-Quang, D. A.; Buczkowicz, P.; Rakopoulos, P.; Liu, X. Y.; Fontebasso, A. M.; Bouffet, E.; Bartels, U.; Albrecht, S.; Schwartzentruber, J.; Letourneau, L.; Bourgey, M.; Bourque, G.; Montpetit, A.; Bourret, G.; Lepage, P.; Fleming, A.; Lichter, P.; Kool, M.; Von Deimling, A.; Sturm, D.; Korshunov, A.; Faury, D.; Jones, D. T.; Majewski, J.; Pfister, S. M.; Jabado, N.; Hawkins, C. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. 2012, 124(3), 439-447.

Silveira, A. B.; Kasper, L. H.; Fan, Y.; Jin, H.; Wu, G.; Shaw, T. I.; Zhu, X.; Larson, J. D.; Easton, J.; Shao, Y.; Yergeau, D. A.; Rosencrance, C.; Boggs, K.; Rusch, M. C.; Ding, L.; Zhang, J.; Finkelstein, D.; Noyes, R. M.; Russell, B. L.; Xu, B.; Broniscer, A.; Wetmore, C.; Pounds, S. B.; Ellison, D. W.; Zhang, J.; Baker, S. J. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol., 2019, 137(4), 637-655.
[http://dx.doi.org/10.1007/s00401-019-01975-4]

Chammas, P.; Mocavini, I.; Di Croce, L. Engaging chromatin: PRC2 structure meets function. Br. J. Cancer, 2019, 122(3), 315-328.
[http://dx.doi.org/10.1038/s41416-019-0615-2]

Lewis, P.W.; Müller, M.M.; Koletsky, M.S.; Cordero, F.; Lin, S.; Banaszynski, L.A.; Garcia, B.A.; Muir, T.W.; Becher, O.J.; Allis, C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science, 2013, 340(6134), 857-861.
[http://dx.doi.org/10.1126/science.1232245] [PMID: 23539183]

Krug, B.; De Jay, N.; Harutyunyan, A. S.; Deshmukh, S.; Marchione, D. M.; Guilhamon, P.; Bertrand, K. C.; Mikael, L. G.; McConechy, M. K.; Chen, C. C. L.; Khazaei, S.; Koncar, R. F.; Agnihotri, S.; Faury, D.; Ellezam, B.; Weil, A. G.; Ursini-Siegel, J.; De Carvalho, D. D.; Dirks, P. B.; Lewis, P. W.; Salomoni, P.; Lupien, M.; Arrowsmith, C.; Lasko, P. F.; Garcia, B. A.; Kleinman, C. L.; Jabado, N.; Mack, S. C. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell, 2019, 35(5), 782-797.e8.
[http://dx.doi.org/10.1016/j.ccell.2019.04.004] [PMID: 31085178]

Nagaraja, S.; Quezada, M.A.; Gillespie, S.M.; Arzt, M.; Lennon, J.J.; Woo, P.J.; Hovestadt, V.; Kambhampati, M.; Filbin, M.G.; Suva, M.L.; Nazarian, J.; Monje, M. Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state. Mol. Cell, 2019, 76(6), 965-980.e12.
[http://dx.doi.org/10.1016/j.molcel.2019.08.030] [PMID: 31588023]

Jonkers, I.; Lis, J.T. Getting up to speed with transcription elongation by RNA polymerase II. Nat. Rev. Mol. Cell Biol., 2015, 16(3), 167-177.
[http://dx.doi.org/10.1038/nrm3953] [PMID: 25693130]

Mackay, A.; Burford, A.; Carvalho, D.; Izquierdo, E.; Fazal-Salom, J.; Taylor, K. R.; Bjerke, L.; Clarke, M.; Vinci, M.; Nandhabalan, M.; Temelso, S.; Popov, S.; Molinari, V.; Raman, P.; Waanders, A. J.; Han, H. J.; Gupta, S.; Marshall, L.; Zacharoulis, S.; Vaidya, S.; Mandeville, H. C.; Bridges, L. R.; Martin, A. J.; Al-Sarraj, S.; Chandler, C.; Ng, H. K.; Li, X.; Mu, K.; Trabelsi, S.; Brahim, D. H. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. 2017, 32(4), 520-537.

Fontebasso, A. M.; Papillon-Cavanagh, S.; Schwartzentruber, J.; Nikbakht, H.; Gerges, N.; Fiset, P. O.; Bechet, D.; Faury, D.; De Jay, N.; Ramkissoon, L. A.; Corcoran, A.; Jones, D. T. W.; Sturm, D.; Johann, P.; Tomita, T.; Goldman, S.; Nagib, M.; Bendel, A.; Goumnerova, L.; Bowers, D. C.; Leonard, J. R.; Rubin, J. B.; Alden, T.; Browd, S.; Geyer, J. R.; Leary, S.; Jallo, G.; Cohen, K.; Gupta, N.; Prados, M. D.; Carret, A. S.; Ellezam, B.; Crevier, L.; Klekner, A.; Bognar, L.; Hauser, P.; Garami, M.; Myseros, J.; Dong, Z.; Siegel, P. M.; Malkin, H.; Ligon, A. H.; Albrecht, S.; Pfister, S. M.; Ligon, K. L.; Majewski, J.; Jabado, N.; Kieran, M. W. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet., 2014, 46(5), 462-466.
[http://dx.doi.org/10.1038/ng.2950]

Piunti, A.; Hashizume, R.; Morgan, M.A.; Bartom, E.T.; Horbinski, C.M.; Marshall, S.A.; Rendleman, E.J.; Ma, Q.; Takahashi, Y-H.; Woodfin, A.R.; Misharin, A.V.; Abshiru, N.A.; Lulla, R.R.; Saratsis, A.M.; Kelleher, N.L.; James, C.D.; Shilatifard, A.; Katagi, H.; Louis, N.; Unruh, D.; Sasaki, T.; He, X.; Zhang, A.; Ma, Q.; Piunti, A.; Shimazu, Y.; Lamano, J.B.; Carcaboso, A.M.; Tian, X.; Seluanov, A.; Gorbunova, V.; Laurie, K.L.; Kondo, A.; Wadhwani, N.R.; Lulla, R.R.; Goldman, S.; Venneti, S.; Becher, O.J.; Zou, L.; Shilatifard, A.; Hashizume, R.; Krug, B.; De Jay, N.; Harutyunyan, A.S.; Deshmukh, S.; Marchione, D.M.; Guilhamon, P.; Bertrand, K.C.; Mikael, L.G.; McConechy, M.K.; Chen, C.C.L.; Khazaei, S.; Koncar, R.F.; Agnihotri, S.; Faury, D.; Ellezam, B.; Weil, A.G.; Ursini-Siegel, J.; De Carvalho, D.D.; Dirks, P.B.; Lewis, P.W.; Salomoni, P.; Lupien, M.; Arrowsmith, C.; Lasko, P.F.; Garcia, B.A.; Kleinman, C.L.; Jabado, N.; Mack, S.C.; Nagaraja, S.; Vitanza, N.A.; Woo, P.J.; Taylor, K.R.; Liu, F.; Zhang, L.; Li, M.; Meng, W.; Ponnuswami, A.; Sun, W.; Ma, J.; Hulleman, E.; Swigut, T.; Wysocka, J.; Tang, Y.; Monje, M.; Hennika, T.; Hu, G.; Olaciregui, N.G.; Barton, K.L.; Ehteda, A.; Chitranjan, A.; Chang, C.; Gifford, A.J.; Tsoli, M.; Ziegler, D.S.; Carcaboso, A.M.; Becher, O.J.; Souweidane, M.M.; Kramer, K.; Pandit-Taskar, N.; Zhou, Z.; Haque, S.; Zanzonico, P.; Carrasquillo, J.A.; Lyashchenko, S.K.; Thakur, S.B.; Donzelli, M.; Turner, R.S.; Lewis, J.S.; Cheung, NK.V.; Larson, S.M.; Dunkel, I.J.; Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; Soffietti, R.; von Deimling, A.; Ellison, D.W.; Grasso, C.S.; Tang, Y.; Truffaux, N.N.; Berlow, N.E.; Liu, L.; Debily, M-A.; Quist, M.J.; Davis, L.E.; Huang, E.C.; Woo, P.J.; Ponnuswami, A.; Chen, S.; Johung, T.B.; Sun, W.; Kogiso, M.; Du, Y.; Qi, L.; Huang, Y.; Hütt-Cabezas, M.; Warren, K.E.; Le Dret, L.; Meltzer, P.S.; Mao, H.; Quezado, M.; van Vuurden, D.G.; Abraham, J.; Fouladi, M.; Svalina, M.N.; Wang, N.; Hawkins, C.; Nazarian, J.; Alonso, M.M.; Raabe, E.H.; Hulleman, E.; Spellman, P.T.; Li, X-N.; Keller, C.; Pal, R.; Grill, J.; Monje, M.; Agger, K.; Cloos, P.A.C.; Christensen, J.; Pasini, D.; Rose, S.; Rappsilber, J.; Issaeva, I.; Canaani, E.; Salcini, A.E.; Helin, K.; Hashizume, R.; Andor, N.; Ihara, Y.; Lerner, R.; Gan, H.; Chen, X.; Fang, D.; Huang, X.; Tom, M.W.; Ngo, V.; Solomon, D.; Mueller, S.; Paris, P.L.; Zhang, Z.; Petritsch, C.; Gupta, N.; Waldman, T.A.; James, C.D.; Taylor, K.R.; Mackay, A.; Truffaux, N.N.; Butterfield, Y.; Morozova, O.; Philippe, C.; Castel, D.; Grasso, C.S.; Vinci, M.; Carvalho, D.; Carcaboso, A.M.; de Torres, C.; Cruz, O.; Mora, J.; Entz-Werle, N.; Ingram, W.J.; Monje, M.; Hargrave, D.; Bullock, A.N.; Puget, S.; Yip, S.; Jones, C.; Grill, J.; Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Med., 2017, 23(5), 457-461.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-3890]

Leszczynska, K.B.; Jayaprakash, C.; Kaminska, B.; Mieczkowski, J. Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas. Front. Genet., 2021, 12, 742561.
[http://dx.doi.org/10.3389/fgene.2021.742561] [PMID: 34646308]

Ostrom, Q.T.; Gittleman, H.; Truitt, G.; Boscia, A.; Kruchko, C.; Barnholtz-Sloan, J.S.; Duncan, D.L. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-oncol., 2018, 20(S4)(Suppl. 4), iv1-iv86.
[http://dx.doi.org/10.1093/neuonc/noy131] [PMID: 30445539]

Mathew, R.K.; Rutka, J.T. Diffuse intrinsic pontine glioma: Clinical features, molecular genetics, and novel targeted therapeutics. J. Korean Neurosurg. Soc., 2018, 61(3), 343-351.
[http://dx.doi.org/10.3340/jkns.2018.0008] [PMID: 29742880]

Pollack, I.F.; Agnihotri, S.; Broniscer, A. Childhood brain tumors: Current management, biological insights, and future directions. J. Neurosurg. Pediatr., 2019, 23(3), 261-273.
[http://dx.doi.org/10.3171/2018.10.PEDS18377] [PMID: 30835699]

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet., 2014, 46(5), 444-450.
[http://dx.doi.org/10.1038/ng.2938] [PMID: 24705251]

Mack, S.C.; Witt, H.; Piro, R.M.; Gu, L.; Zuyderduyn, S.; Stütz, A.M.; Wang, X.; Gallo, M.; Garzia, L.; Zayne, K.; Zhang, X.; Ramaswamy, V.; Jäger, N.; Jones, D.T.W.; Sill, M.; Pugh, T.J.; Ryzhova, M.; Wani, K.M.; Shih, D.J.H.; Head, R.; Remke, M.; Bailey, S.D.; Zichner, T.; Faria, C.C.; Barszczyk, M.; Stark, S.; Seker-Cin, H.; Hutter, S.; Johann, P.; Bender, S.; Hovestadt, V.; Tzaridis, T.; Dubuc, A.M.; Northcott, P.A.; Peacock, J.; Bertrand, K.C.; Agnihotri, S.; Cavalli, F.M.G.; Clarke, I.; Nethery-Brokx, K.; Creasy, C.L.; Verma, S.K.; Koster, J.; Wu, X.; Yao, Y.; Milde, T.; Sin-Chan, P.; Zuccaro, J.; Lau, L.; Pereira, S.; Castelo-Branco, P.; Hirst, M.; Marra, M.A.; Roberts, S.S.; Fults, D.; Massimi, L.; Cho, Y.J.; Van Meter, T.; Grajkowska, W.; Lach, B.; Kulozik, A.E.; von Deimling, A.; Witt, O.; Scherer, S.W.; Fan, X.; Muraszko, K.M.; Kool, M.; Pomeroy, S.L.; Gupta, N.; Phillips, J.; Huang, A.; Tabori, U.; Hawkins, C.; Malkin, D.; Kongkham, P.N.; Weiss, W.A.; Jabado, N.; Rutka, J.T.; Bouffet, E.; Korbel, J.O.; Lupien, M.; Aldape, K.D.; Bader, G.D.; Eils, R.; Lichter, P.; Dirks, P.B.; Pfister, S.M.; Korshunov, A.; Taylor, M.D. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature, 2014, 506(7489), 445-450.
[http://dx.doi.org/10.1038/nature13108] [PMID: 24553142]

Pajtler, K.W.; Witt, H.; Sill, M.; Jones, D.T.W.; Hovestadt, V.; Kratochwil, F.; Wani, K.; Tatevossian, R.; Punchihewa, C.; Johann, P.; Reimand, J.; Warnatz, H.J.; Ryzhova, M.; Mack, S.; Ramaswamy, V.; Capper, D.; Schweizer, L.; Sieber, L.; Wittmann, A.; Huang, Z.; van Sluis, P.; Volckmann, R.; Koster, J.; Versteeg, R.; Fults, D.; Toledano, H.; Avigad, S.; Hoffman, L.M.; Donson, A.M.; Foreman, N.; Hewer, E.; Zitterbart, K.; Gilbert, M.; Armstrong, T.S.; Gupta, N.; Allen, J.C.; Karajannis, M.A.; Zagzag, D.; Hasselblatt, M.; Kulozik, A.E.; Witt, O.; Collins, V.P.; von Hoff, K.; Rutkowski, S.; Pietsch, T.; Bader, G.; Yaspo, M.L.; von Deimling, A.; Lichter, P.; Taylor, M.D.; Gilbertson, R.; Ellison, D.W.; Aldape, K.; Korshunov, A.; Kool, M.; Pfister, S.M. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell, 2015, 27(5), 728-743.
[http://dx.doi.org/10.1016/j.ccell.2015.04.002] [PMID: 25965575]

Kilday, J.-P.; Rahman, R.; Dyer, S.; Ridley, L.; Lowe, J.; Coyle, B.; Grundy, R. Pediatric ependymoma: Biological perspectives. 2009.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0584]

Ostrom, Q. T.; Gittleman, H.; Liao, P.; Rouse, C.; Chen, Y.; Dowling, J.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
[http://dx.doi.org/10.1093/neuonc/nou223]

Grill, J.; Le Deley, M.C.; Gambarelli, D.; Raquin, M.A.; Couanet, D.; Pierre-Kahn, A.; Habrand, J.L.; Doz, F.; Frappaz, D.; Gentet, J.C.; Edan, C.; Chastagner, P.; Kalifa, C. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: A multicenter trial of the French Society of Pediatric Oncology. J. Clin. Oncol., 2001, 19(5), 1288-1296.
[http://dx.doi.org/10.1200/JCO.2001.19.5.1288] [PMID: 11230470]

Gatta, G.; Botta, L.; Rossi, S.; Aareleid, T.; Bielska-Lasota, M.; Clavel, J.; Dimitrova, N.; Jakab, Z.; Kaatsch, P.; Lacour, B.; Mallone, S.; Marcos-Gragera, R.; Minicozzi, P.; Sánchez-Pérez, M.J.; Sant, M.; Santaquilani, M.; Stiller, C.; Tavilla, A.; Trama, A.; Visser, O.; Peris-Bonet, R. Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—a population-based study. Lancet Oncol., 2014, 15(1), 35-47.
[http://dx.doi.org/10.1016/S1470-2045(13)70548-5] [PMID: 24314616]

Merchant, T.E.; Li, C.; Xiong, X.; Kun, L.E.; Boop, F.A.; Sanford, R.A. Conformal radiotherapy after surgery for paediatric ependymoma: A prospective study. Lancet Oncol., 2009, 10(3), 258-266.
[http://dx.doi.org/10.1016/S1470-2045(08)70342-5] [PMID: 19274783]

Massimino, M.; Miceli, R.; Giangaspero, F.; Boschetti, L.; Modena, P.; Antonelli, M.; Ferroli, P.; Bertin, D.; Pecori, E.; Valentini, L.; Biassoni, V.; Garrè, M.L.; Schiavello, E.; Sardi, I.; Cama, A.; Viscardi, E.; Scarzello, G.; Scoccianti, S.; Mascarin, M.; Quaglietta, L.; Cinalli, G.; Diletto, B.; Genitori, L.; Peretta, P.; Mussano, A.; Buccoliero, A.; Calareso, G.; Barra, S.; Mastronuzzi, A.; Giussani, C.; Marras, C.E.; Balter, R.; Bertolini, P.; Giombelli, E.; La Spina, M.; Buttarelli, F.R.; Pollo, B.; Gandola, L. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-oncol., 2016, 18(10), 1451-1460.
[http://dx.doi.org/10.1093/neuonc/now108] [PMID: 27194148]

Johnson, R.A.; Wright, K.D.; Poppleton, H.; Mohankumar, K.M.; Finkelstein, D.; Pounds, S.B.; Rand, V.; Leary, S.E.S.; White, E.; Eden, C.; Hogg, T.; Northcott, P.; Mack, S.; Neale, G.; Wang, Y.D.; Coyle, B.; Atkinson, J.; DeWire, M.; Kranenburg, T.A.; Gillespie, Y.; Allen, J.C.; Merchant, T.; Boop, F.A.; Sanford, R.A.; Gajjar, A.; Ellison, D.W.; Taylor, M.D.; Grundy, R.G.; Gilbertson, R.J. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature, 2010, 466(7306), 632-636.
[http://dx.doi.org/10.1038/nature09173] [PMID: 20639864]

Mohankumar, K.M.; Currle, D.S.; White, E.; Boulos, N.; Dapper, J.; Eden, C.; Nimmervoll, B.; Thiruvenkatam, R.; Connelly, M.; Kranenburg, T.A.; Neale, G.; Olsen, S.; Wang, Y.D.; Finkelstein, D.; Wright, K.; Gupta, K.; Ellison, D.W.; Thomas, A.O.; Gilbertson, R.J. An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. Nat. Genet., 2015, 47(8), 878-887.
[http://dx.doi.org/10.1038/ng.3323] [PMID: 26075792]

Carter, M.; Nicholson, J.; Ross, F.; Crolla, J.; Allibone, R.; Balaji, V.; Perry, R.; Walker, D.; Gilbertson, R.; Ellison, D. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br. J. Cancer, 2002, 86(6), 929-939.
[http://dx.doi.org/10.1038/sj.bjc.6600180] [PMID: 11953826]

Witt, H.; Mack, S.C.; Ryzhova, M.; Bender, S.; Sill, M.; Isserlin, R.; Benner, A.; Hielscher, T.; Milde, T.; Remke, M.; Jones, D.T.W.; Northcott, P.A.; Garzia, L.; Bertrand, K.C.; Wittmann, A.; Yao, Y.; Roberts, S.S.; Massimi, L.; Van Meter, T.; Weiss, W.A.; Gupta, N.; Grajkowska, W.; Lach, B.; Cho, Y.J.; von Deimling, A.; Kulozik, A.E.; Witt, O.; Bader, G.D.; Hawkins, C.E.; Tabori, U.; Guha, A.; Rutka, J.T.; Lichter, P.; Korshunov, A.; Taylor, M.D.; Pfister, S.M. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell, 2011, 20(2), 143-157.
[http://dx.doi.org/10.1016/j.ccr.2011.07.007] [PMID: 21840481]

Parker, M.; Mohankumar, K.M.; Punchihewa, C.; Weinlich, R.; Dalton, J.D.; Li, Y.; Lee, R.; Tatevossian, R.G.; Phoenix, T.N.; Thiruvenkatam, R.; White, E.; Tang, B.; Orisme, W.; Gupta, K.; Rusch, M.; Chen, X.; Li, Y.; Nagahawhatte, P.; Hedlund, E.; Finkelstein, D.; Wu, G.; Shurtleff, S.; Easton, J.; Boggs, K.; Yergeau, D.; Vadodaria, B.; Mulder, H.L.; Becksfort, J.; Gupta, P.; Huether, R.; Ma, J.; Song, G.; Gajjar, A.; Merchant, T.; Boop, F.; Smith, A.A.; Ding, L.; Lu, C.; Ochoa, K.; Zhao, D.; Fulton, R.S.; Fulton, L.L.; Mardis, E.R.; Wilson, R.K.; Downing, J.R.; Green, D.R.; Zhang, J.; Ellison, D.W.; Gilbertson, R.J. C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature, 2014, 506(7489), 451-455.
[http://dx.doi.org/10.1038/nature13109] [PMID: 24553141]

Lewis, R.; Li, Y.D.; Hoffman, L.; Hashizume, R.; Gravohac, G.; Rice, G.; Wadhwani, N.R.; Jie, C.; Pundy, T.; Mania-Farnell, B.; Mayanil, C.S.; Soares, M.B.; Lei, T.; James, C.D.; Foreman, N.K.; Tomita, T.; Xi, G. Global reduction of H3K4me3 improves chemotherapeutic efficacy for pediatric ependymomas. Neoplasia, 2019, 21(6), 505-515.
[http://dx.doi.org/10.1016/j.neo.2019.03.012] [PMID: 31005631]

Gilbertson, R.J.; Bentley, L.; Hernan, R.; Junttila, T.T.; Frank, A.J.; Haapasalo, H.; Connelly, M.; Wetmore, C.; Curran, T.; Elenius, K.; Ellison, D.W. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin. Cancer Res., 2002, 8(10), 3054-3064.
[PMID: 12374672]

Panwalkar, P.; Clark, J.; Ramaswamy, V.; Hawes, D.; Yang, F.; Dunham, C.; Yip, S.; Hukin, J.; Sun, Y.; Schipper, M.J.; Chavez, L.; Margol, A.; Pekmezci, M.; Chung, C.; Banda, A.; Bayliss, J.M.; Curry, S.J.; Santi, M.; Rodriguez, F.J.; Snuderl, M.; Karajannis, M.A.; Saratsis, A.M.; Horbinski, C.M.; Carret, A.S.; Wilson, B.; Johnston, D.; Lafay-Cousin, L.; Zelcer, S.; Eisenstat, D.; Silva, M.; Scheinemann, K.; Jabado, N.; McNeely, P.D.; Kool, M.; Pfister, S.M.; Taylor, M.D.; Hawkins, C.; Korshunov, A.; Judkins, A.R.; Venneti, S. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol., 2017, 134(5), 705-714.
[http://dx.doi.org/10.1007/s00401-017-1752-4] [PMID: 28733933]

Ahuja, N.; Sharma, A.R.; Baylin, S.B. Epigenetic therapeutics: A new weapon in the war against cancer. Annu. Rev. Med., 2016, 67(1), 73-89.
[http://dx.doi.org/10.1146/annurev-med-111314-035900] [PMID: 26768237]

Cheng, Y.; He, C.; Wang, M.; Ma, X.; Mo, F.; Yang, S.; Han, J.; Wei, X. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct. Target. Ther., 2019, 4(1), 62.
[http://dx.doi.org/10.1038/s41392-019-0095-0] [PMID: 31871779]

Roberti, A.; Valdes, A.F.; Torrecillas, R.; Fraga, M.F.; Fernandez, A.F. Epigenetics in cancer therapy and nanomedicine. Clin. Epigenetics, 2019, 11(1), 81.
[http://dx.doi.org/10.1186/s13148-019-0675-4] [PMID: 31097014]

Agger, K.; Cloos, P.A.C.; Christensen, J.; Pasini, D.; Rose, S.; Rappsilber, J.; Issaeva, I.; Canaani, E.; Salcini, A.E.; Helin, K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature, 2007, 449(7163), 731-734.
[http://dx.doi.org/10.1038/nature06145] [PMID: 17713478]

Hashizume, R.; Andor, N.; Ihara, Y.; Lerner, R.; Gan, H.; Chen, X.; Fang, D.; Huang, X.; Tom, M.W.; Ngo, V.; Solomon, D.; Mueller, S.; Paris, P.L.; Zhang, Z.; Petritsch, C.; Gupta, N.; Waldman, T.A.; James, C.D. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med., 2014, 20(12), 1394-1396.
[http://dx.doi.org/10.1038/nm.3716] [PMID: 25401693]

Nikolaev, A.; Fiveash, J. B.; Yang, E. S. Combined targeting of mutant P53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int. J. Mol. Sci., 2020, 21(2), 490.
[http://dx.doi.org/10.3390/ijms21020490]

Bykov, V.J.N.; Eriksson, S.E.; Bianchi, J.; Wiman, K.G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer, 2018, 18(2), 89-102.
[http://dx.doi.org/10.1038/nrc.2017.109] [PMID: 29242642]

Rasmussen, T.A.; Tolstrup, M.; Møller, H.J.; Brinkmann, C.R.; Olesen, R.; Erikstrup, C.; Laursen, A.L.; Østergaard, L.; Søgaard, O.S. Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: A pilot study to assess effects on the central nervous system. Open Forum Infect. Dis., 2015, 2(1), ofv037.
[http://dx.doi.org/10.1093/ofid/ofv037] [PMID: 26034779]

Grasso, C.S.; Tang, Y.; Truffaux, N.; Berlow, N.E.; Liu, L.; Debily, M.A.; Quist, M.J.; Davis, L.E.; Huang, E.C.; Woo, P.J.; Ponnuswami, A.; Chen, S.; Johung, T.B.; Sun, W.; Kogiso, M.; Du, Y.; Qi, L.; Huang, Y.; Hütt-Cabezas, M.; Warren, K.E.; Le Dret, L.; Meltzer, P.S.; Mao, H.; Quezado, M.; van Vuurden, D.G.; Abraham, J.; Fouladi, M.; Svalina, M.N.; Wang, N.; Hawkins, C.; Nazarian, J.; Alonso, M.M.; Raabe, E.H.; Hulleman, E.; Spellman, P.T.; Li, X.N.; Keller, C.; Pal, R.; Grill, J.; Monje, M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med., 2015, 21(6), 555-559.
[http://dx.doi.org/10.1038/nm.3855] [PMID: 25939062]

Hennika, T.; Hu, G.; Olaciregui, N.G.; Barton, K.L.; Ehteda, A.; Chitranjan, A.; Chang, C.; Gifford, A.J.; Tsoli, M.; Ziegler, D.S.; Carcaboso, A.M.; Becher, O.J. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One, 2017, 12(1), e0169485-e0169485.
[http://dx.doi.org/10.1371/journal.pone.0169485] [PMID: 28052119]

Phi, J.H.; Choi, S.A.; Kwak, P.A.; Lee, J.Y.; Wang, K.C.; Hwang, D.W.; Kim, S.K. Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model. Oncotarget, 2017, 8(34), 56747-56757.
[http://dx.doi.org/10.18632/oncotarget.18132] [PMID: 28915627]

Groselj, B.; Sharma, N.L.; Hamdy, F.C.; Kerr, M.; Kiltie, A.E. Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair. Br. J. Cancer, 2013, 108(4), 748-754.
[http://dx.doi.org/10.1038/bjc.2013.21] [PMID: 23361058]

Milde, T.; Lodrini, M.; Savelyeva, L.; Korshunov, A.; Kool, M.; Brueckner, L.M.; Antunes, A.S.L.M.; Oehme, I.; Pekrun, A.; Pfister, S.M.; Kulozik, A.E.; Witt, O.; Deubzer, H.E. HD-MB03 is a novel group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J. Neurooncol., 2012, 110(3), 335-348.
[http://dx.doi.org/10.1007/s11060-012-0978-1] [PMID: 23054560]

Halsall, J.A.; Turan, N.; Wiersma, M.; Turner, B.M. Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics Chromatin, 2015, 8(1), 29.
[http://dx.doi.org/10.1186/s13072-015-0021-9] [PMID: 26380582]

Brown, Z.Z.; Müller, M.M.; Jain, S.U.; Allis, C.D.; Lewis, P.W.; Muir, T.W. Strategy for “detoxification” of a cancer-derived histone mutant based on mapping its interaction with the methyltransferase PRC2. J. Am. Chem. Soc., 2014, 136(39), 13498-13501.
[http://dx.doi.org/10.1021/ja5060934] [PMID: 25180930]

Anastas, J.N.; Zee, B.M.; Kalin, J.H.; Kim, M.; Guo, R.; Alexandrescu, S.; Blanco, M.A.; Giera, S.; Gillespie, S.M.; Das, J.; Wu, M.; Nocco, S.; Bonal, D.M.; Nguyen, Q.D.; Suva, M.L.; Bernstein, B.E.; Alani, R.; Golub, T.R.; Cole, P.A.; Filbin, M.G.; Shi, Y. Reprograming chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell, 2019, 36(5), 528-544.e10.
[http://dx.doi.org/10.1016/j.ccell.2019.09.005] [PMID: 31631026]

Vitanza, N.A.; Biery, M.C.; Myers, C.; Ferguson, E.; Zheng, Y.; Girard, E.J.; Przystal, J.M.; Park, G.; Noll, A.; Pakiam, F.; Winter, C.A.; Morris, S.M.; Sarthy, J.; Cole, B.L.; Leary, S.E.S.; Crane, C.; Lieberman, N.A.P.; Mueller, S.; Nazarian, J.; Gottardo, R.; Brusniak, M.Y.; Mhyre, A.J.; Olson, J.M. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. Neuro-oncol., 2021, 23(3), 376-386.
[http://dx.doi.org/10.1093/neuonc/noaa249] [PMID: 33130903]

Lin, G.L.; Wilson, K.M.; Ceribelli, M.; Stanton, B.Z.; Woo, P.J.; Kreimer, S.; Qin, E.Y.; Zhang, X.; Lennon, J.; Nagaraja, S.; Morris, P.J.; Quezada, M.; Gillespie, S.M.; Duveau, D.Y.; Michalowski, A.M.; Shinn, P.; Guha, R.; Ferrer, M.; Klumpp-Thomas, C.; Michael, S.; McKnight, C.; Minhas, P.; Itkin, Z.; Raabe, E.H.; Chen, L.; Ghanem, R.; Geraghty, A.C.; Ni, L.; Andreasson, K.I.; Vitanza, N.A.; Warren, K.E.; Thomas, C.J.; Monje, M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci. Transl. Med., 2019, 11(519), eaaw0064.
[http://dx.doi.org/10.1126/scitranslmed.aaw0064] [PMID: 31748226]

Ehteda, A.; Simon, S.; Franshaw, L.; Giorgi, F.M.; Liu, J.; Joshi, S.; Rouaen, J.R.C.; Pang, C.N.I.; Pandher, R.; Mayoh, C.; Tang, Y.; Khan, A.; Ung, C.; Tolhurst, O.; Kankean, A.; Hayden, E.; Lehmann, R.; Shen, S.; Gopalakrishnan, A.; Trebilcock, P.; Gurova, K.; Gudkov, A.V.; Norris, M.D.; Haber, M.; Vittorio, O.; Tsoli, M.; Ziegler, D.S. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Rep., 2021, 35(2), 108994.
[http://dx.doi.org/10.1016/j.celrep.2021.108994] [PMID: 33852836]

Sandberg, D.I.; Yu, B.; Patel, R.; Hagan, J.; Miesner, E.; Sabin, J.; Smith, S.; Fletcher, S.; Shah, M.N.; Sirianni, R.W.; Taylor, M.D. Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: A pilot clinical trial. J. Neurooncol., 2019, 141(2), 449-457.
[http://dx.doi.org/10.1007/s11060-018-03055-1] [PMID: 30460634]

Banik, D.; Moufarrij, S.; Villagra, A. Immunoepigenetics combination therapies: An overview of the role of HDACs in cancer immunotherapy. Int. J. Mol. Sci., 2019, 20(9), 2241.
[http://dx.doi.org/10.3390/ijms20092241] [PMID: 31067680]

Tan, J.; Yang, X.; Zhuang, L.; Jiang, X.; Chen, W.; Lee, P.L.; Karuturi, R.K.M.; Tan, P.B.O.; Liu, E.T.; Yu, Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev., 2007, 21(9), 1050-1063.
[http://dx.doi.org/10.1101/gad.1524107] [PMID: 17437993]

Majello, B.; Gorini, F.; Saccà, C.; Amente, S. Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers (Basel), 2019, 11(3), 324.
[http://dx.doi.org/10.3390/cancers11030324] [PMID: 30866496]

Fu, X.; Zhang, P.; Yu, B. Advances toward LSD1 inhibitors for cancer therapy. Future Med. Chem., 2017, 9(11), 1227-1242.
[http://dx.doi.org/10.4155/fmc-2017-0068] [PMID: 28722477]

Bailey, C.P.; Figueroa, M.; Gangadharan, A.; Yang, Y.; Romero, M.M.; Kennis, B.A.; Yadavilli, S.; Henry, V.; Collier, T.; Monje, M.; Lee, D.A.; Wang, L.; Nazarian, J.; Gopalakrishnan, V.; Zaky, W.; Becher, O.J.; Chandra, J. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro-oncol., 2020, 22(9), 1302-1314.
[http://dx.doi.org/10.1093/neuonc/noaa058] [PMID: 32166329]

Piunti, A.; Hashizume, R.; Morgan, M.A.; Bartom, E.T.; Horbinski, C.M.; Marshall, S.A.; Rendleman, E.J.; Ma, Q.; Takahashi, Y.; Woodfin, A.R.; Misharin, A.V.; Abshiru, N.A.; Lulla, R.R.; Saratsis, A.M.; Kelleher, N.L.; James, C.D.; Shilatifard, A. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat. Med., 2017, 23(4), 493-500.
[http://dx.doi.org/10.1038/nm.4296] [PMID: 28263307]

Hatch, S.B.; Yapp, C.; Montenegro, R.C.; Savitsky, P.; Gamble, V.; Tumber, A.; Ruda, G.F.; Bavetsias, V.; Fedorov, O.; Atrash, B.; Raynaud, F.; Lanigan, R.; Carmichael, L.; Tomlin, K.; Burke, R.; Westaway, S.M.; Brown, J.A.; Prinjha, R.K.; Martinez, E.D.; Oppermann, U.; Schofield, C.J.; Bountra, C.; Kawamura, A.; Blagg, J.; Brennan, P.E.; Rossanese, O.; Müller, S. Assessing histone demethylase inhibitors in cells: Lessons learned. Epigenetics Chromatin, 2017, 10(1), 9.
[http://dx.doi.org/10.1186/s13072-017-0116-6] [PMID: 28265301]

Fiskus, W.; Sharma, S.; Shah, B.; Portier, B.P.; Devaraj, S.G.T.; Liu, K.; Iyer, S.P.; Bearss, D.; Bhalla, K.N. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 2014, 28(11), 2155-2164.
[http://dx.doi.org/10.1038/leu.2014.119] [PMID: 24699304]

Seo, B.R.; Min, K.; Cho, I.J.; Kim, S.C.; Kwon, T.K. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVPBEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One, 2014, 9(4), e95588.
[http://dx.doi.org/10.1371/journal.pone.0095588] [PMID: 24743574]

Fujisawa, T.; Filippakopoulos, P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat. Rev. Mol. Cell Biol., 2017, 18(4), 246-262.
[http://dx.doi.org/10.1038/nrm.2016.143] [PMID: 28053347]

Nagaraja, S.; Vitanza, N.A.; Woo, P.J.; Taylor, K.R.; Liu, F.; Zhang, L.; Li, M.; Meng, W.; Ponnuswami, A.; Sun, W.; Ma, J.; Hulleman, E.; Swigut, T.; Wysocka, J.; Tang, Y.; Monje, M. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell, 2017, 31(5), 635-652.e6.
[http://dx.doi.org/10.1016/j.ccell.2017.03.011] [PMID: 28434841]

Taylor, I.C.; Hütt-Cabezas, M.; Brandt, W.D.; Kambhampati, M.; Nazarian, J.; Chang, H.T.; Warren, K.E.; Eberhart, C.G.; Raabe, E.H. Disrupting NOTCH slows diffuse intrinsic pontine glioma growth, enhances radiation sensitivity, and shows combinatorial efficacy with bromodomain inhibition. J. Neuropathol. Exp. Neurol., 2015, 74(8), 778-790.
[http://dx.doi.org/10.1097/NEN.0000000000000216] [PMID: 26115193]

Bandopadhayay, P.; Bergthold, G.; Nguyen, B.; Schubert, S.; Gholamin, S.; Tang, Y.; Bolin, S.; Schumacher, S.E.; Zeid, R.; Masoud, S.; Yu, F.; Vue, N.; Gibson, W.J.; Paolella, B.R.; Mitra, S.S.; Cheshier, S.H.; Qi, J.; Liu, K.W.; Wechsler-Reya, R.; Weiss, W.A.; Swartling, F.J.; Kieran, M.W.; Bradner, J.E.; Beroukhim, R.; Cho, Y.J. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin. Cancer Res., 2014, 20(4), 912-925.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2281] [PMID: 24297863]

Henssen, A.; Thor, T.; Odersky, A.; Heukamp, L.; El-Hindy, N.; Beckers, A.; Speleman, F.; Althoff, K.; Schäfers, S.; Schramm, A.; Sure, U.; Fleischhack, G.; Eggert, A.; Schulte, J.H. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget, 2013, 4(11), 2080-2095.
[http://dx.doi.org/10.18632/oncotarget.1534] [PMID: 24231268]

Groves, A.; Clymer, J.; Filbin, M.G. Bromodomain and extra-terminal protein inhibitors: Biologic insights and therapeutic potential in pediatric brain tumors. Pharmaceuticals (Basel), 2022, 15(6), 665.
[http://dx.doi.org/10.3390/ph15060665] [PMID: 35745584]

Venkataraman, S.; Alimova, I.; Balakrishnan, I.; Harris, P.; Birks, D.K.; Griesinger, A.; Amani, V.; Cristiano, B.; Remke, M.; Taylor, M.D.; Handler, M.; Foreman, N.K.; Vibhakar, R. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget, 2014, 5(9), 2355-2371.
[http://dx.doi.org/10.18632/oncotarget.1659] [PMID: 24796395]

Long, J.; Li, B.; Rodriguez-Blanco, J.; Pastori, C.; Volmar, C.H.; Wahlestedt, C.; Capobianco, A.; Bai, F.; Pei, X.H.; Ayad, N.G.; Robbins, D.J. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J. Biol. Chem., 2014, 289(51), 35494-35502.
[http://dx.doi.org/10.1074/jbc.M114.595348] [PMID: 25355313]

Zhang, H.; Pandey, S.; Travers, M.; Sun, H.; Morton, G.; Madzo, J.; Chung, W.; Khowsathit, J.; Perez-Leal, O.; Barrero, C.A.; Merali, C.; Okamoto, Y.; Sato, T.; Pan, J.; Garriga, J.; Bhanu, N.V.; Simithy, J.; Patel, B.; Huang, J.; Raynal, N.J.M.; Garcia, B.A.; Jacobson, M.A.; Kadoch, C.; Merali, S.; Zhang, Y.; Childers, W.; Abou-Gharbia, M.; Karanicolas, J.; Baylin, S.B.; Zahnow, C.A.; Jelinek, J.; Graña, X.; Issa, J.P.J. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell, 2018, 175(5), 1244-1258.e26.
[http://dx.doi.org/10.1016/j.cell.2018.09.051] [PMID: 30454645]

Dahl, N.A.; Danis, E.; Balakrishnan, I.; Wang, D.; Pierce, A.; Walker, F.M.; Gilani, A.; Serkova, N.J.; Madhavan, K.; Fosmire, S.; Green, A.L.; Foreman, N.K.; Venkataraman, S.; Vibhakar, R. Super elongation complex as a targetable dependency in diffuse midline glioma. Cell Rep., 2020, 31(1), 107485.
[http://dx.doi.org/10.1016/j.celrep.2020.03.049] [PMID: 32268092]

Zhou, Q.; Li, T.; Price, D. H. RNA polymerase II elongation control. 2012, 81, 119-143.
[http://dx.doi.org/10.1146/annurev-biochem-052610-095910]

Peterlin, B.M.; Price, D.H. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell, 2006, 23(3), 297-305.
[http://dx.doi.org/10.1016/j.molcel.2006.06.014] [PMID: 16885020]

Ott, M.; Litzenburger, U.M.; Sahm, F.; Rauschenbach, K.J.; Tudoran, R.; Hartmann, C.; Marquez, V.E.; von Deimling, A.; Wick, W.; Platten, M. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One, 2012, 7(10), e47663.
[http://dx.doi.org/10.1371/journal.pone.0047663] [PMID: 23077658]

Xu, M.Z.; Chan, S.W.; Liu, A.M.; Wong, K.F.; Fan, S.T.; Chen, J.; Poon, R.T.; Zender, L.; Lowe, S.W.; Hong, W.; Luk, J.M. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene, 2011, 30(10), 1229-1240.
[http://dx.doi.org/10.1038/onc.2010.504] [PMID: 21076472]

Li, M.; Lu, J.; Zhang, F.; Li, H.; Zhang, B.; Wu, X.; Tan, Z.; Zhang, L.; Gao, G.; Mu, J.; Shu, Y.; Bao, R.; Ding, Q.; Wu, W.; Dong, P.; Gu, J.; Liu, Y. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett., 2014, 355(2), 201-209.
[http://dx.doi.org/10.1016/j.canlet.2014.08.036] [PMID: 25218593]

Ma, S.; Meng, Z.; Chen, R.; Guan, K.L. The hippo pathway: Biology and pathophysiology. Annu. Rev. Biochem., 2019, 88(1), 577-604.
[http://dx.doi.org/10.1146/annurev-biochem-013118-111829] [PMID: 30566373]

Meel, M.H.; de Gooijer, M.C.; Metselaar, D.S.; Sewing, A.C.P.; Zwaan, K.; Waranecki, P.; Breur, M.; Buil, L.C.M.; Lagerweij, T.; Wedekind, L.E.; Twisk, J.W.R.; Koster, J.; Hashizume, R.; Raabe, E.H.; Montero Carcaboso, Á.; Bugiani, M.; Phoenix, T.N.; van Tellingen, O.; van Vuurden, D.G.; Kaspers, G.J.L.; Hulleman, E. Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma. Clin. Cancer Res., 2020, 26(13), 3319-3332.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-3538] [PMID: 32165429]

Prendergast, L.; Hong, E.; Safina, A.; Poe, D.; Gurova, K. Histone chaperone FACT is essential to overcome replication stress in mammalian cells. Oncogene, 2020, 39(28), 5124-5137.
[http://dx.doi.org/10.1038/s41388-020-1346-9] [PMID: 32533099]

Barbour, H.; Daou, S.; Hendzel, M.; Affar, E.B. Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes. Nat. Commun., 2020, 11(1), 5947.
[http://dx.doi.org/10.1038/s41467-020-19722-9] [PMID: 33230107]

Balakrishnan, I.; Danis, E.; Pierce, A.; Madhavan, K.; Wang, D.; Dahl, N.; Sanford, B.; Birks, D.K.; Davidson, N.; Metselaar, D.S.; Meel, M.H.; Lemma, R.; Donson, A.; Vijmasi, T.; Katagi, H.; Sola, I.; Fosmire, S.; Alimova, I.; Steiner, J.; Gilani, A.; Hulleman, E.; Serkova, N.J.; Hashizume, R.; Hawkins, C.; Carcaboso, A.M.; Gupta, N.; Monje, M.; Jabado, N.; Jones, K.; Foreman, N.; Green, A.; Vibhakar, R.; Venkataraman, S. Senescence induced by BMI1 inhibition is a therapeutic vulnerability in H3K27M-mutant DIPG. Cell Rep., 2020, 33(3), 108286.
[http://dx.doi.org/10.1016/j.celrep.2020.108286] [PMID: 33086074]

Wiese, M.; Hamdan, F.H.; Kubiak, K.; Diederichs, C.; Gielen, G.H.; Nussbaumer, G.; Carcaboso, A.M.; Hulleman, E.; Johnsen, S.A.; Kramm, C.M. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. Cell Death Dis., 2020, 11(8), 673.
[http://dx.doi.org/10.1038/s41419-020-02800-7] [PMID: 32826850]

Hoeman, C.; Shen, C.; Becher, O.J. CDK4/6 and PDGFRA signaling as therapeutic targets in diffuse intrinsic pontine glioma. Front. Oncol., 2018, 8, 191.
[http://dx.doi.org/10.3389/fonc.2018.00191] [PMID: 29904623]

Wang, Z.; Xu, C.; Diplas, B.H.; Moure, C.J.; Chen, C.P.J.; Chen, L.H.; Du, C.; Zhu, H.; Greer, P.K.; Zhang, L.; He, Y.; Waitkus, M.S.; Yan, H. Targeting mutant PPM1D sensitizes diffuse intrinsic pontine glioma cells to the PARP inhibitor olaparib. Mol. Cancer Res., 2020, 18(7), 968-980.
[http://dx.doi.org/10.1158/1541-7786.MCR-19-0507] [PMID: 32229503]

Li, J.; Hao, D.; Wang, L.; Wang, H.; Wang, Y.; Zhao, Z.; Li, P.; Deng, C.; Di, L. Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy. Sci. Rep., 2017, 7(1), 4035.
[http://dx.doi.org/10.1038/s41598-017-04406-0] [PMID: 28642588]

Sun, W.; Lv, S.; Li, H.; Cui, W.; Wang, L. Enhancing the anticancer efficacy of immunotherapy through combination with histone modification inhibitors. Genes (Basel), 2018, 9(12), 633.
[http://dx.doi.org/10.3390/genes9120633] [PMID: 30558227]

Cossío, F.P.; Esteller, M.; Berdasco, M. Towards a more precise therapy in cancer: Exploring epigenetic complexity. Curr. Opin. Chem. Biol., 2020, 57, 41-49.
[http://dx.doi.org/10.1016/j.cbpa.2020.04.008] [PMID: 32480315]

Jones, P.A.; Issa, J.P.J.; Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet., 2016, 17(10), 630-641.
[http://dx.doi.org/10.1038/nrg.2016.93] [PMID: 27629931]

Jones, P.A.; Ohtani, H.; Chakravarthy, A.; De Carvalho, D.D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer, 2019, 19(3), 151-161.
[http://dx.doi.org/10.1038/s41568-019-0109-9] [PMID: 30723290]

Kantarjian, H.; Issa, J.P.J.; Rosenfeld, C.S.; Bennett, J.M.; Albitar, M.; DiPersio, J.; Klimek, V.; Slack, J.; de Castro, C.; Ravandi, F.; Helmer, R., III; Shen, L.; Nimer, S.D.; Leavitt, R.; Raza, A.; Saba, H. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer, 2006, 106(8), 1794-1803.
[http://dx.doi.org/10.1002/cncr.21792] [PMID: 16532500]

Yi, J.; Wu, J. Epigenetic regulation in medulloblastoma. Mol. Cell. Neurosci., 2018, 87, 65-76.
[http://dx.doi.org/10.1016/j.mcn.2017.09.003] [PMID: 29269116]

Singh, M.M.; Manton, C.A.; Bhat, K.P.; Tsai, W.W.; Aldape, K.; Barton, M.C.; Chandra, J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-oncol., 2011, 13(8), 894-903.
[http://dx.doi.org/10.1093/neuonc/nor049] [PMID: 21653597]

Butler, C.; Sprowls, S.; Szalai, G.; Arsiwala, T.; Saralkar, P.; Straight, B.; Hatcher, S.; Tyree, E.; Yost, M.; Kohler, W.J.; Wolff, B.; Putnam, E.; Lockman, P.; Liu, T. Hypomethylating agent azacitidine is effective in treating brain metastasis triple-negative breast cancer through regulation of DNA methylation of keratin 18 gene. Transl. Oncol., 2020, 13(6), 100775.
[http://dx.doi.org/10.1016/j.tranon.2020.100775] [PMID: 32408199]

Zhang, Y.; Zhou, L.; Safran, H.; Borsuk, R.; Lulla, R.; Tapinos, N.; Seyhan, A.A.; El-Deiry, W.S. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia, 2021, 23(8), 792-810.
[http://dx.doi.org/10.1016/j.neo.2021.06.007] [PMID: 34246076]